Multiple sclerosis is a major cause of neurologic disability, which accrues predominantly during progressive forms of the disease. While development of multifocal inflammatory lesions is the underlying pathologic process in relapsing-remitting multiple sclerosis, the gradual accumulation of disability that characterizes progressive multiple sclerosis appears to result from more diffuse immune mechanisms and neurodegeneration. As a result, the13 anti-inflammatory medications with regulatory approval to treat relapsing-remitting multiple sclerosis have little or no efficacy in progressive multiple sclerosis without inflammatory lesion activity. Thus, effective therapies for progressive multiple sclerosis that prevent worsening, reverse damage, and restore function represent major unmet needs. This review summarizes the current status of therapy for progressive multiple sclerosis and outlines prospects for the future.
Introduction
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system. The global prevalence of MS was estimated at 2·3 million in 2013, 1 Disability in MS accrues predominantly in the progressive forms of the disease, creating a significant healthcare burden at the individual, family, and community levels. Although substantial progress has been made in the treatment of RRMS -13 medications currently have regulatory approval -development of therapies that prevent or reverse progression has been slower. International efforts such as the International Progressive MS Alliance are increasing the focus on PMS and identifying specific research areas to target. 2 This review summarizes the current status of therapy for progressive MS and outlines prospects for the future.
Current understanding of the pathogenesis of progressive multiple sclerosis
The pathogenic mechanisms underlying progression are incompletely understood. Moreover, since the division 25 years ago of what previously was called chronic progressive MS into PPMS and SPMS, it remains uncertain whether they represent overlapping or distinct entities. 3 Patients with PPMS and SPMS both exhibit gradually worsening disability, most often motor impairment with a pattern suggesting a myelopathy but also may have progressive hemiparesis, ataxia, visual dysfunction, or cognitive impairment. While the onset of progression commonly occurs at age 40-50 in both groups, SPMS follows an initial RR phase typically lasting [10] [11] [12] [13] [14] [15] years. Patients with PPMS have an equal gender balance, while SPMS more commonly affects Page 5 follicles. 9 The severity of cortical demyelination correlates with the extent of meningeal inflammation in PMS, suggesting a pathogenic role. 10 A number of potential mechanisms are hypothesized to lead to neurodegeneration in PMS (Figure 1 ), 11 many of which are potential therapeutic targets. Demyelinated axons are abundant in longstanding MS and are hypothesized to be susceptible to chronic injury. 6 In addition to loss of myelin's structural and trophic support, chronic demyelination might permit increased exposure to toxic species in the microenvironment: inflammatory mediators, and reactive oxygen and iron species. In some demyelinated axons, saltatory nerve impulse conduction is replaced by continuous conduction, which restores function but increases energy demand and sodium accumulation in the axonal cytoplasm. Resultant reverse operation of sodium-calcium exchanger to restore ionic gradients could lead to cytoplasmic calcium accumulation, activation of calpains, and proteolysis of cytoskeleton. As discussed below, studies of sodium channel blockers had mixed results. 12, 13 Although remyelination can be seen in some lesions, the failure of remyelination in other areas is hypothesized to cause axonal degeneration and disease progression. Thus, remyelination is a potential therapeutic goal. The abundance of oligodendrocyte precursors in some chronic lesions suggests that lack of such cells does not explain failure of remyelination. 14 Rather, the absence of factors necessary for successful remyelination or the presence of inhibitory factors is more likely responsible. This concept has important implications for potential repair-promoting strategies.
Axonal injury also is a major contributor to irreversible disability. This injury is believed to occur through a combination of acute inflammatory damage, degeneration of chronically demyelinated axons in white and gray matter, and antegrade and retrograde trans-synaptic degeneration due to distal axonal transection. 15 There is increasing evidence that mitochondrial dysfunction in axons results from impaired mitochondrial transport, susceptibility to oxidative injury, and mutations in mitochondrial DNA, all of which lead to impaired energy production and generation of reactive oxygen species. The net effect of these processes is accumulation of Page 6 various toxic species, increased cellular energy demand, failure of energy production, and virtual hypoxia resulting in neurodegeneration. Improved energy production is the proposed mechanism of action of high-dose biotin.
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Revised multiple sclerosis phenotype classification
Increasing recognition that relapses and MRI lesion activity occur in some patients with PMS, mainly in the early stages, led to recent revision of the phenotypic categories of PMS ( Figure   2 ). 17 The new scheme still differentiates progression at disease onset (PPMS) from progression after an initial RR course (SPMS) but adds two qualifiers: presence or absence of clinical relapses or new MRI lesions ("active" or "not active"), and presence or absence of gradual worsening disability independent of relapses ("with progression" or "without progression").
These qualifiers are intended to be re-assessed over time, e.g. annually, with patients potentially changing category based on recent disease course.
The new classification will have significant benefits in recognizing two relatively separate facets of PMS -inflammatory lesion activity and gradual progression. The classification will be especially helpful for selection of informative clinical trial participants. As discussed below, the presence of recent relapses or active MRI lesions is an important determinant of efficacy in PMS of medications with predominantly anti-inflammatory effects. It is hoped that in the future, phenotypic classification will incorporate additional imaging and non-imaging biomarkers, genetic markers, and epigenetic factors to categorize patients more comprehensively.
Clinical measures of disability
Clinical outcome measures must take into account heterogeneous clinical manifestations, unpredictable course, and generally slow rate of worsening in PMS. The current measures address these issues in different ways. 18 The Kurtzke Expanded Disability Status Scale (EDSS)
is based on the neurologic examination and assesses a range of neurological functions, 21 Several smartphone and wearable motion sensors have been developed, which provide the ability to measure community-based ambulation and physical activity. How such data can be used to assess therapies in clinical trials or to make therapeutic decisions in practice is unclear at present. Nevertheless, it is expected that MS disability assessment will undergo further refinement to include various performance measures. Methods for capturing large segments of data using the electronic medical record also will expand in the future.
The role of imaging in progressive multiple sclerosis Page 8 MRI is a key diagnostic tool in all forms of MS. In addition, because of the greater sensitivity of MRI compared to clinical outcomes, a standard approach in the development of antiinflammatory therapies for RRMS employs MRI lesion activity in phase 2 trials to predict benefit on relapses in subsequent phase 3 trials. 22 Such a marker is lacking in PMS where lesion activity is less common than in RRMS and disability often worsens without lesion accrual.
Moreover, due to its limited pathologic specificity, standard MRI does not appear to detect the pathologic processes that underlie disability progression. Several imaging approaches under development show promise to meet this need.
Brain volume measures
Whole brain atrophy, which reflects aggregate tissue injury, is more severe in PMS compared to RRMS, though the rate of volume loss is relatively constant over the course of the disease. 23 Whole brain atrophy correlates with physical 23 and cognitive 24 impairment. Treatment effects on brain atrophy predict effects on disability, at least in RRMS. 25 Methods for measuring whole brain volume are reasonably well established, and published sample size estimates for PMS trials based on whole brain atrophy are feasible. 26 The main disadvantage as a phase 2 trial outcome is the rather slow rate of change, prolonging trial duration. In addition, precise whole brain volume measurement is technically challenging and subject to significant biologic variability, making it difficult to implement in clinical practice.
Methods to detect gray matter pathology
Conventional MRI does not detect cortical lesions, an important site of MS injury. Specialized sequences like double inversion recovery 27 and ultra-high field (7 tesla) MRI 28 allow identification of some but not all cortical lesions. Because of the insensitivity of current techniques to demonstrate cortical pathology directly, some studies have measured cortical thickness or volume to quantify pathology indirectly. Cortical atrophy is prominent in PMS Page 9 correlates with physical 30 and cognitive 31 impairment. Atrophy of deep gray structures (thalamus, caudate, and hippocampus) also occurs in PMS and can be focal (presumably due to lesions) or more diffuse (presumably due to damage to afferent or efferent connections). 32, 33 Like whole brain atrophy measures, regional atrophy measures require substantial image postprocessing, making them more suitable for research studies than clinical practice.
"Advanced" MRI techniques
Several MRI techniques may provide improved pathologic specificity and, thus, better correlation with clinical disability: diffusion tensor imaging (DTI, which quantifies the threedimensional diffusion of water), 34 magnetization transfer imaging (MTI, which quantifies tissue integrity through the interaction of protons bound to molecular structures and free water), 35 magnetic resonance spectroscopy (which quantifies tissue metabolites), 36 and techniques such as magnetic resonance fingerprinting. 37 These techniques can be applied to the whole brain, or selectively to gray or white matter lesions, or regions that appear normal on standard MRI. All of these techniques show promise but require further validation of their pathologic specificity.
Spinal cord imaging
Spinal cord atrophy correlates with clinical measures of disability. 38 Quantitative and more pathologically specific MRI measures of spinal cord are difficult due to low spatial resolution, pulsation artifact, cerebrospinal fluid partial volume averaging, and challenges in registration.
Nevertheless, assessment of the spinal cord using DTI, 39 MTR, 40 and spectroscopy 41 may provide important insights in PMS.
Positron emission tomography
Page 10
Positron emission tomography markers for activated microglia 42 and myelin 43 have been developed that potentially could assess disease status in PMS. This technique's principal shortcoming is its limited spatial resolution.
Optical coherence tomography
Optical coherence tomography is a rapid, non-invasive technique that provides high-resolution quantification of the retinal nerve fiber layer (the axons that extend to the optic nerve) and the corresponding neuronal cells bodies in the ganglion cell layer. These measures directly reflect the axonal integrity of the optic nerves and correlate with overall clinical disability 44 and brain MRI measures.
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Status of disease therapy for progressive multiple sclerosis
Anti-inflammatory strategies
Most medications approved for RRMS have been tested in PMS (Table 1) . Interferon-β1 therapies were evaluated in SPMS shortly after their efficacy was demonstrated in RRMS.
Although two trials were positive, 46,47 several others were negative. [48] [49] [50] Similarly, a phase 3 trial of glatiramer acetate in PPMS was negative. 51 Subsequent analysis found that trials enriched with participants with recent relapses and MRI lesion activity tended to demonstrate benefit from interferon-β1. 52 Similar results were observed with other anti-inflammatory therapies in PMS.
Fingolimod, a sphingosine 1-phosphate (S1P) receptor modulator, reduced relapses, MRI lesion activity, and brain volume loss in three phase 3 trials in RRMS. [53] [54] [55] Fingolimod readily enters the brain and has direct effects on several central nervous system cell types mediated by S1P receptors, suggesting it might be beneficial in PMS. 56 A phase 3 trial of fingolimod in PPMS demonstrated reduction in new MRI lesions but not the risk of confirmed disability worsening measured by a composite outcome that included EDSS, T25FW, and 9HPT. 20 These results Page 11 indicate that entry of a medication into the central nervous system and direct actions there do not ensure efficacy in PMS.
Another highly effective anti-inflammatory therapy, the anti-1 integrin monoclonal antibody natalizumab, was evaluated in a phase 3 trial in SPMS. Natalizumab therapy did not slow worsening of disability measured by a composite outcome similar to that used to test fingolimod, though benefit was seen on 9HPT. 57 The lack of benefit on progression of natalizumab, one of the more potent anti-inflammatory therapies for RRMS, underscores the importance of mechanism of action in determining efficacy.
Because of the potent efficacy of anti-CD20 monoclonal antibodies in RRMS, there is increased recognition of the multifaceted role of B lymphocytes in MS pathogenesis beyond antibody production. 58 In a phase 3 trial in PPMS, rituximab treatment slowed the change in lesion volume relative to placebo, but did not decrease the risk of confirmed disability progression. 59 In planned subgroup analyses, participants younger than 50 years and those with gadolinium-enhancing lesions at baseline showed benefit on disability progression. Based on those results, a humanized anti-B lymphocyte monoclonal antibody, ocrelizumab, was evaluated in PPMS. This phase 3 trial demonstrated that ocrelizumab reduced the risk of disability progression by 24%. 60 Importantly, this trial enrolled relatively young participants (mean age 44.6 years; maximum 55 years), with short disease duration (mean 6.4 years; maximum 15 years), and a relatively high proportion with gadolinium-enhancing lesions at baseline (26%).
The subgroup with gadolinium-enhancing lesions at baseline appeared to have a greater reduction in risk of disability progression, though the difference was not significant. 61 The different results obtained in PMS trials appear not to relate to differences in antiinflammatory potency. Instead, the results suggest that those trials enrolling a study population with younger age, shorter disease duration, and more ongoing inflammatory lesion activity tend to demonstrate greater benefit. Conversely, older patients without lesion activity gain little if any benefit as a group. In addition to study population, mechanism of action also may be relevant, Page 12 although that requires further study. These observations provide valuable guidance for both the characteristics of participants to enroll in future trials and the choice of therapies to study in PMS.
Neuroprotective therapeutic strategies
The limited success of anti-inflammatory agents in treating PMS suggests that other therapeutic approaches, such as neuroprotective or repair-promoting strategies, will be necessary. A phase 2 study assessed the potential cytoprotective properties of simvastatin in SPMS. 62 Simvastatin produced a 43% reduction in whole brain volume loss and a slowing in disability worsening measured by EDSS (absolute difference in means of 0.25 points). Another trial utilized a repurposed sodium-channel blocker, phenytoin, to protect axons from acute inflammatory injury in acute optic neuritis. 12 Phenytoin treatment within two weeks of onset led to a 30% decrease in loss of retinal nerve fiber layer thickness relative to placebo. This success is in contrast to the negative results with another sodium channel blocker, lamotrigine, in slowing brain volume loss in SPMS. 13 This discrepancy may relate to a "pseudo-atrophy" effect seen in the first year of the lamotrigine study, which may have obscured a potential benefit. Similarly, the neuroprotective effects of cannabinoids observed in the laboratory were not confirmed in a trial of the synthetic cannabinoid, dronabinol in PPMS and SPMS. Treatment did not reduce disability worsening over three years. 63 The low progression rate in the placebo group decreased the ability of this study to demonstrate benefit.
Cellular energy metabolism appears to be abnormal in PMS 11 and is another potential therapeutic target. The vitamin biotin is a coenzyme for many essential carboxylases and, in high doses, is hypothesized to enhance cellular energy production with resultant improved axonal function, decreased neurodegeneration, and enhanced remyelination. 64 A placebocontrolled phase 3 trial evaluated whether high dose biotin (300 mg/day) improved disability in Page 13 SPMS and PPMS. 16 The study found that 13% of treated participants had improvement in measures of disability, compared to none in the placebo group.
Repair-promoting strategies
LINGO-1 is a protein expressed by oligodendrocytes and neurons that inhibits remyelination. 65 Treatment of patients with acute optic neuritis with the LINGO-1-blocking monoclonal antibody BIIB033 did not improve recovery of visual evoked potential latency, a measure of optic nerve conduction, in the primary analysis but was effective in a post-hoc "per-protocol" analysis. 66 Negative results of a phase 2 trial assessing whether BIIB033 improves disability in RRMS and SPMS (clinicaltrials.gov identifier NCT01864148) recently were announced.
Cell-based repair-promoting strategies have received much attention as a potential therapeutic approach in PMS. Oligodendrocyte progenitor cells (OPCs) can be isolated from fetal human brain and when injected intracerebrally into hypomyelinating shiverer mice, lead to widespread myelination and reversal of the clinical phenotype. 67 A phase 1 dose-escalation trial to evaluate the feasibility and safety of intracerebral injections of these cells in SPMS currently is planned. 68 An intriguing related approach involves using OPCs 69 or OPC-like induced pluripotent stem cells 70 as the basis for high-throughput screening of already available drugs for their ability to stimulate remyelination. Molecules identified in the initial screens were further evaluated by increasingly stringent in vitro and in vivo testing, identifying the muscarinic antagonist benztropine, the antihistamine clemastine, the imidazole antifungal miconazole, and the topical steroid clobetasol as potential candidates for further testing. A pilot study of clemastine showed improvement on visual evoked potentials in participants with MS-related chronic optic neuropathy. 71 Significant work has assessed mesenchymal stem cell (MSC) transplantation as a potential repair-promoting strategy in MS. 72 MSCs are pluripotent precursor cells that can be isolated Page 14 from bone marrow, adipose tissue, and numerous other tissues, and culture-expanded to purity.
They exhibit numerous immunomodulatory, tissue-protective, and repair-promoting properties. 72 Following several preliminary studies in MS showing good safety and tolerability, the ongoing MESEMS phase 2 trial (clinicaltrials.gov identifier NCT01854957) should provide more definitive evidence concerning safety and efficacy. However, important methodological questions remain, including preferred source (bone marrow versus adipose tissue), cell production protocol to optimize yield and potency, whether the cells can be cryopreserved or need to be administered immediately, best route of administration (intravenous, intrathecal, or intra-arterial), appropriate dose and dosing schedule, and whether the cells should be derived from the patient (autologous) or someone without MS (allogeneic).
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Future directions
The largely disappointing results of studies of anti-inflammatory agents in PMS indicate that therapeutics that target other mechanisms will be necessary. One obstacle to development of such strategies is our incomplete understanding of the pathophysiology of progression.
Therefore, the range of approaches under investigation remains relatively broad and without a clear pattern of success as yet. MS-SMART (clinicaltrials.gov identifier NCT01910259) is applying an adaptive trial design to evaluate three putative neuroprotective agents, amiloride, riluzole, and fluoxetine. A second significant obstacle is the lack of a validated phase 2 trial methodology that reliably predicts success of neuroprotective and repair-promoting strategies in phase 3 studies. Two general approaches have been utilized to date: recovery from an acute lesion involving an eloquent pathway (e.g. the optic nerve), or an imaging biomarker (e.g. whole brain atrophy). The eloquent pathway approach has the advantage of sensitivity, but the relevance to PMS of lessening damage or improving recovery from a focal acute inflammatory lesion is uncertain. Conversely, assessing whole brain or regional volume loss appears more likely to measure preservation of tissue integrity relevant to PMS but may be insufficiently Page 15 sensitive for a phase 2 trial. In addition to testing the efficacy of ibudilast in PPMS and SPMS, the SPRINT-MS trial (clinicaltrials.gov identifier NCT01982942) is evaluating the relative sensitivity of whole brain and regional atrophy measures, DTI, MTI, and OCT to detect neuroprotection for use in proof-of-concept clinical trials. At the present time, however, the population most likely to benefit from neuroprotective or repair-promoting strategies and the optimal trial design to demonstrate benefit have yet to be defined.
Restorative and rehabilitation approaches
Persons with PMS must manage increasing disability from a wide range of complex interacting symptoms, with impairments of gait, vision, and cognition considered the most relevant for those who have lived with MS for over 15 years. 73 Given the paucity of pharmacologic treatments for these symptoms, restorative and rehabilitation approaches form the mainstay of their management; highlighted as a key priority by the International Progressive MS Alliance. 2 While most studies of physiotherapy and multi-disciplinary rehabilitation have focused on RRMS, there is some evidence that these approaches are effective in improving ability and participation, and importantly health-related quality of life and coping skills in patients with PMS. 74 However, a recent systematic review found that, while 13 studies showed benefit in at least one outcome measure, all either were under-powered or had methodological issues. 74 Adequately designed clinical trials will be necessary to advance rehabilitation for PMS.
There is some evidence to suggest that exercise, incorporating endurance or resistance training, is feasible in MS, 75 and improving physical fitness benefits not only physical but also cognitive function. 76 Addressing the multiplicity of symptoms in PMS may require a combination of approaches and utilise a range of outcomes. A recent pilot trial used three forms of exercise and demonstrated benefit in both mobility and cognition. 77 Similarly, a recent study showed augmented benefit from combining exercise with symptomatic therapy. 78 For more disabled patients, use of robotics may be helpful. 79 Results for gait and balance training have been Page 16 encouraging, though trial sizes were relatively small. Some benefits also were seen for upper limb function weakness and incoordination.
Numerous studies have demonstrated neuroplasticity in MS, measured with functional imaging and, more recently, physiological techniques at the synaptic level. 80, 81 There is a body of evidence suggesting that functional reorganisation following a relapse helps restore function.
At a cellular level, synaptic plasticity appears to make an important contribution to recovery in MS. Long-term potentiation of synaptic transmission may functionally compensate for neuronal loss through increasing synaptic excitability of denervated neurons. This phenomenon has been demonstrated following relapse but not yet in progression. The challenge will be to incorporate approaches that target these mechanisms into active rehabilitation programmes. This issue is compounded in PMS by more limited cognitive and motor reserve.
Finally, management of PMS presents a number of other challenges. This population is older with increased likelihood of comorbidities. 82 Recognition and treatment of conditions such as musculoskeletal disorders, diabetes, cardiac disease, and respiratory dysfunction are necessary to maximise levels of ability and participation. In addition, awareness of the factors that lead to falls -inevitably associated with increasing disability and therefore more common in PMS -and preventative measures to avoid them, is essential. 83 Over and above all of these approaches, embracing a holistic concept of wellness and encouraging lifestyle choices across physical, emotional, social, intellectual, occupational, and spiritual dimensions is a key element of a comprehensive management plan and one that is strongly advocated by people with MS. 84 This approach serves to underline the importance of self-management at all stages of MS.
Conclusions
The pathogenic mechanisms underlying acute relapses and progression differ, though both processes probably co-exist to varying degrees throughout the course of MS. Therapies 
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